Literature DB >> 28807240

Role of exosomes in treatment of hepatocellular carcinoma.

Demetrios Moris1, Eliza W Beal1, Jeffery Chakedis1, Richard A Burkhart2, Carl Schmidt1, Mary Dillhoff1, Xufeng Zhang1, Stamatios Theocharis3, Timothy M Pawlik4.   

Abstract

Exosomes are nanovesicles that may play a role in intercellular communication by acting as carriers of functional contents such as proteins, lipids, RNA molecules and circulating DNA from donor to recipient cells. In addition, exosomes may play a potential role in immunosurveillance and tumor pathogenesis and progression. Recently, research has increasingly focused on the role of exosomes in hepatocellular carcinoma (HCC), the most common primary liver malignancy. We herein review data on emerging experimental and clinical studies focused on the role of exosomes in the pathogenesis, diagnosis, progression and chemotherapy response of patients with HCC. Beyond their diagnostic value in HCC, exosomes are involved in different mechanisms of HCC tumor pathogenesis and progression including angiogenesis and immune escape. Moreover, exosomes have been demonstrated to change the tumor microenvironment to a less tolerogenic state, favoring immune response and tumor suppression. These results underline a practical and potentially feasible role of exosomes in the treatment of patients with HCC, both as a target and a vehicle for drug design. Future studies will need to further elucidate the exact role and reliability of exosomes as screening, diagnostic and treatment targets in patients with HCC.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Cirrhosis; Exosomes; Hepatitis; Hepatocellular carcinoma; Liver; Therapy; miRNA

Mesh:

Substances:

Year:  2017        PMID: 28807240     DOI: 10.1016/j.suronc.2017.04.005

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  16 in total

1.  Synovial fluid-derived exosomal lncRNA PCGEM1 as biomarker for the different stages of osteoarthritis.

Authors:  Ye Zhao; Juan Xu
Journal:  Int Orthop       Date:  2018-08-20       Impact factor: 3.075

2.  Pathways of production and delivery of hepatocyte exosomes.

Authors:  Li Chen; Ruju Chen; Sherri Kemper; David R Brigstock
Journal:  J Cell Commun Signal       Date:  2017-10-23       Impact factor: 5.782

Review 3.  The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity.

Authors:  Stavros P Papadakos; Nikolaos Dedes; Elias Kouroumalis; Stamatios Theocharis
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

4.  Exosomal miR-4800-3p Aggravates the Progression of Hepatocellular Carcinoma via Regulating the Hippo Signaling Pathway by Targeting STK25.

Authors:  Haoming Lin; Jicai Peng; Taifeng Zhu; Meihong Xiong; Rui Zhang; Liming Lei
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 5.  Dairy consumption and hepatocellular carcinoma risk.

Authors:  Bodo C Melnik
Journal:  Ann Transl Med       Date:  2021-04

6.  Prognostic Value of Complement Component 2 and Its Correlation with Immune Infiltrates in Hepatocellular Carcinoma.

Authors:  Gang Ning; Yan-Lin Huang; Li-Min Zhen; Wen-Xiong Xu; Xue-Jun Li; Li-Na Wu; Ying Liu; Chan Xie; Liang Peng
Journal:  Biomed Res Int       Date:  2020-06-14       Impact factor: 3.411

7.  Exosome-transmitted long non-coding RNA SENP3-EIF4A1 suppresses the progression of hepatocellular carcinoma.

Authors:  Jianchu Wang; Jian Pu; Ying Zhang; Tianwei Yao; Zongjiang Luo; Wenchuan Li; Guidan Xu; Juan Liu; Wujun Wei; Yibin Deng
Journal:  Aging (Albany NY)       Date:  2020-06-27       Impact factor: 5.682

8.  Serum exosomal long noncoding RNAs lnc-FAM72D-3 and lnc-EPC1-4 as diagnostic biomarkers for hepatocellular carcinoma.

Authors:  Zhicheng Yao; Changchang Jia; Yan Tai; Hao Liang; Zhaozhong Zhong; Zhiyong Xiong; Meihai Deng; Qi Zhang
Journal:  Aging (Albany NY)       Date:  2020-06-18       Impact factor: 5.682

9.  Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma.

Authors:  Li Sun; Yingying Su; Xiangxiang Liu; Mu Xu; Xiaoxiang Chen; Yefei Zhu; Zhirui Guo; Tingting Bai; Lin Dong; Chenchen Wei; Xiaoxiao Cai; Bangshun He; Yuqin Pan; Huiling Sun; Shukui Wang
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

10.  Exosomal miR-638 Inhibits Hepatocellular Carcinoma Progression by Targeting SP1.

Authors:  Jing Yang; Bo Li; Shuo Zhao; Hongyu Du; Yaming Du
Journal:  Onco Targets Ther       Date:  2020-07-07       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.